tbuckley/cabot-search huggingface dataset:
Survival impact of complete cytoreductive surgery in the primary management of FIGO stage IIIC, high-grade, epithelial ovarian cancer
Authors: A. Santillan, E. Tanner III, M. Guile, Z. Mulla, T. P. Diaz-Montes, R. L. Giuntoli II, R. E. Bristow
Journal: Journal of Clinical Oncology (2008)

16551 Background: To evaluate the influence of complete primary surgical cytoreduction and other prognostic variables on overall survival among patients with FIGO stage IIIC, high grade, epithelial ovarian cancer. Methods: Ninety-three consecutive patients undergoing primary cytoreductive surgery for FIGO-stage IIIC high-grade epithelial ovarian carcinoma between 1997 and 2005 were retrospectively identified from the tumor registry database. Clinical data were abstracted from the medical record: age, ASA, presence of ascites, presence of carcinomatosis, residual disease, use of radical procedures, pre-operative serum albumin, and pre-operative serum CA-125. Survival estimates were calculated using the Kaplan and Meier method. Univariate and multivariate regression analyses were used was used to identify independent variables associated with improved survival. Fisher exact test was used for proportion variables. Results: The median age was 62 years (range=37 to 83 years), and 96% of patients had serous histology. Carcinomatosis was present in 80.4 % of patients. All patients received platinum based chemotherapy following primary surgery. The median follow-up time was 27 months (range=1 to 124 months). Radical procedures were used in 59% of all patients. The overall rate of significant morbidity associated with primary cytoreductive surgery was 25%. Optimal cytoreduction (residual ≤ l cm) was achieved in 78/93 patients (83.8%). Complete cytoreduction (no gross residual) was achieved in 43/93 patients (46.2%) and was associated with a median survival of 58.4 months, compared to 30.1 months for patients with residual disease 0.1-l.0 cm and 24.4 months for patients with suboptimal residual disease (p= 0.005). Residual disease was the only significant and independent predictor of survival (adjusted hazard ratio (AHR) =2.35, p=0.0002). Conclusions: Numerous clinical variables have been reported to have prognostic value in advanced ovarian carcinoma. When all patients receive platinum-based chemotherapy post-operatively, the only statistically significant and independent predictor of overall survival is diameter of the largest residual tumor among patients with large-volume, high-grade ovarian cancer. No significant financial relationships to disclose.
Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease
Authors: Floris Imhann, Arnau Vich Vila, Marc Jan Bonder, Jingyuan Fu, Dirk Gevers, Marijn C Visschedijk, Lieke M Spekhorst, Rudi Alberts, Lude Franke, Hendrik M van Dullemen, Rinze W F Ter Steege, Curtis Huttenhower, Gerard Dijkstra, Ramnik J Xavier, Eleonora A M Festen, Cisca Wijmenga, Alexandra Zhernakova, Rinse K Weersma
Journal: Gut (2016)

Objective Patients with IBD display substantial heterogeneity in clinical characteristics. We hypothesise that individual differences in the complex interaction of the host genome and the gut microbiota can explain the onset and the heterogeneous presentation of IBD. Therefore, we performed a case–control analysis of the gut microbiota, the host genome and the clinical phenotypes of IBD. Design Stool samples, peripheral blood and extensive phenotype data were collected from 313 patients with IBD and 582 truly healthy controls, selected from a population cohort. The gut microbiota composition was assessed by tag-sequencing the 16S rRNA gene. All participants were genotyped. We composed genetic risk scores from 11 functional genetic variants proven to be associated with IBD in genes that are directly involved in the bacterial handling in the gut: NOD2 , CARD9 , ATG16L1 , IRGM and FUT2 . Results Strikingly, we observed significant alterations of the gut microbiota of healthy individuals with a high genetic risk for IBD: the IBD genetic risk score was significantly associated with a decrease in the genus Roseburia in healthy controls (false discovery rate 0.017). Moreover, disease location was a major determinant of the gut microbiota: the gut microbiota of patients with colonic Crohn's disease (CD) is different from that of patients with ileal CD, with a decrease in alpha diversity associated to ileal disease (p=3.28×10 −13 ). Conclusions We show for the first time that genetic risk variants associated with IBD influence the gut microbiota in healthy individuals. Roseburia spp are acetate-to-butyrate converters, and a decrease has already been observed in patients with IBD.
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial
Authors: Thomas J. Johnston, Greg L. Shaw, Alastair D. Lamb, Deepak Parashar, David Greenberg, Tengbin Xiong, Alison L. Edwards, Vincent Gnanapragasam, Peter Holding, Phillipa Herbert, Michael Davis, Elizabeth Mizielinsk, J. Athene Lane, Jon Oxley, Mary Robinson, Malcolm Mason, John Staffurth, Prasad Bollina, James Catto, Andrew Doble, Alan Doherty, David Gillatt, Roger Kockelbergh, Howard Kynaston, Steve Prescott, Alan Paul, Philip Powell, Derek Rosario, Edward Rowe, Jenny L. Donovan, Freddie C. Hamdy, David E. Neal
Journal: European Urology (2016)

Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial. Mortality was compared for 492 men followed up for a median of 7.4 yr to a contemporaneous cohort of men from the UK Anglia Cancer Network (ACN) and with a matched subset from the ACN. PCa-specific and all-cause mortality were compared using Kaplan-Meier analysis and Cox's proportional hazards regression. Of the 492 men excluded from the ProtecT cohort, 37 (8%) had metastases (N1, M0 = 5, M1 = 32) and 305 had locally advanced disease (62%). The median PSA was 17 μg/l. Treatments included radical prostatectomy (RP; n = 54; 11%), radiotherapy (RT; n = 245; 50%), androgen deprivation therapy (ADT; n = 122; 25%), other treatments (n = 11; 2%), and unknown (n = 60; 12%). There were 49 PCa-specific deaths (10%), of whom 14 men had received radical treatment (5%); and 129 all-cause deaths (26%). In matched ProtecT and ACN cohorts, 37 (9%) and 64 (16%), respectively, died of PCa, while 89 (22%) and 103 (26%) died of all causes. ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; p = 0.0037), but mortality was similar in those treated radically. The nonrandomised design is a limitation. Men with PSA-detected advanced PCa excluded from ProtecT and treated radically had low rates of PCa death at 7.4-yr follow-up. Among men who underwent nonradical treatment, the ProtecT group had a lower rate of PCa death. Early detection through PSA testing, leadtime bias, and group heterogeneity are possible factors in this finding. Prostate cancer that has spread outside the prostate gland without causing symptoms can be detected via prostate-specific antigen testing and treated, leading to low rates of death from this disease.
A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix®) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802
Authors: R. Casaretti, P. Comella, C. Carlomagno, L. Maiorino, E. Greco, A. Russo, G. Sanna, M.L. Barzelloni, B. Massidda, V. Formica, C. Serci, S. Defraia, G. Palmieri, M.T. Ionta
Journal: Annals of Oncology (2015)
O-007 Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
Authors: E. Van Cutsem, K. Muro, D. Cunningham, G. Bodoky, A. Sobrero, S. Cascinu, J. Ajani, A. Ohtsu, C. Oh Sang, S.-E. Al-Batran, Z. Wainberg, R. Hozak, H. Ouyang, S. Melemed, D. Ferry, H. Wilke
Journal: Annals of Oncology (2016)
PPAR-γリガンドは脳性Na利尿ペプチド産生を抑制し低酸素-再酸素化時の心線維芽細胞リモデリングを調節する(PPAR-r Ligands Attenuated Brain Natriuretic Peptide Production and Affect Remodeling in Cardiac Fibroblasts in Hypoxia-Reoxygenation)
Authors: Makino Naoki, Sugano Masahiro, Sato Shinji, Oyama Junichi, Suematsu Nobuhiro
Journal: Circulation (2004)
Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era
Authors: Matthew J Maurer, Herve Ghesquieres, Stephen M Ansell, Carrie A Thompson, Grzegorz S. Nowakowski, David J. Inwards, Cristine Allmer, Emmanuelle Nicolas-Virelizier, Catherine Sebban, Pierre Biron, Catherine Chassagne-Clement, Therese Gargi, William R Macon, Andrew L. Feldman, Sergei I Syrbu, Susan L Slager, Thomas E. Witzig, Thomas M Habermann, Brian K Link, James R Cerhan
Journal: Blood (2014)
Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force
Authors: Silvia Villa, Friederike Kendel, Lionne Venderbos, Tiziana Rancati, Chris Bangma, Peter Carroll, Louis Denis, Laurence Klotz, Ida J. Korfage, Athene J. Lane, Tiziana Magnani, Ken Mastris, Antti Rannikko, Monique Roobol, Bruce Trock, Roderick Van den Bergh, Hendrik Van Poppel, Riccardo Valdagni, Lara Bellardita
Journal: European Urology (2016)
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC
Authors: Ingrid Arijs, Gert De Hertogh, Bart Lemmens, Leentje Van Lommel, Magali de Bruyn, Wiebe Vanhove, Isabelle Cleynen, Kathleen Machiels, Marc Ferrante, Frans Schuit, Gert Van Assche, Paul Rutgeerts, Severine Vermeire
Journal: Gut (2016)

Objective Lymphocyte recruitment to the inflamed gut is increased in UC. Inhibition of this cell trafficking by vedolizumab (VDZ) was successful in inducing and maintaining remission and in induction of endoscopic mucosal healing. There are no data on histological healing with VDZ. We studied histological changes following VDZ therapy and compared gene expression in patients with UC before and after therapy. Design Forty-one patients with UC from GEMINI I and LTS were studied before and at three time points (weeks 6/12/52) following VDZ therapy. Colonic biopsies were scored using the Geboes index and correlated with Mayo endoscopic subscore. Gene expression was analysed using Affymetrix gene arrays. Results Fifty-five per cent of patients achieving endoscopic healing (= Mayo endoscopic subscore 0–1) with VDZ at the studied time points also had histological healing (= Geboes grade 0–1). In most healers, some residual histological changes (eg, disturbed architecture and increased mononuclear cell infiltrate) were still observed, although this was less at week 52. VDZ restored expression of many inflammatory genes in patients with endoscopic healing only at week 52 and not before. In VDZ healers, the expression of many genes remained dysregulated at weeks 6/12/52 compared with controls. Conclusions VDZ induces histological healing in &gt;50% of patients with endoscopic healing, with maximal effect at week 52. VDZ also restored, although incompletely, the colonic expression of many immune-related genes in patients with UC achieving endoscopic healing at week 52. However, persistent histological and gene dysregulations did remain even in healers, suggesting that maintenance therapy will be necessary to control the intestinal inflammation. Trial registration numbers: NCT00783718 and NCT00790933 ; post-results.
Recurrence risk of breast cancer intrinsic subtypes over time.
Authors: N. Ribelles, L. Perez-Villa, B. Pajares, J. M. Jerez, L. Vicioso, B. Jimenez, V. de Luque, L. Franco, M. Alvarez, L. G. Perez-Rivas, A. Sanchez-Muñoz, E. Gallego, A. Marquez, I. Hierro, E. Alba
Journal: Journal of Clinical Oncology (2011)

e21047 Background: Gene expression profiling and their immunohistochemistry-based surrogates have consistently revealed prognostically significant breast cancer (BC) subtypes: Luminal A (Lum A), Luminal B (Lum B), Luminal-HER2 (Lum-HER2), HER2-enriched (HER2), Basal-like (BL) and Triple negative phenotype-nonbasal (TNP-nb). In addition, there are clinical evidence that hazard of BC recurrence varies over time with two peaks of high risk at 18-24 and 60 months. This study compares the time-related patterns of recurrence within BC subtypes. Methods: Tissue microarrays were constructed from 799 early BC patients diagnosed and treated at our hospital from 1982 to 2005 with available archival paraffin tissue blocks. BC subtypes were defined using an immunopanel of ER, progesterone receptor, HER2, epidermal growth factor receptor, cytokeratin 5/6 and Ki67 by prespecified published methods. Univariate and multivariate analysis (Cox regression) were performed on progression-free survival. Smoothed curves for hazard rates (HR) were estimated by a Kernel-like smoothing procedure. The statistical analysis was done by using the R software environment. Results: Cases were classified as follows: Lum A 368, Lum B 218, Lum-HER2 33, HER2 44, BL 94, TNP-nb 42. With a median follow up of 80 months age, tumor size, nodal status, adjuvant hormonotherapy and intrinsic subtypes were independent prognostic factors. HER2 and BL show high and early peak in HR curves and decreasing sharply to 36 and 48 months respectively. HR in Lum A, Lum B and TNP-nb exhibit a smoother and nearly steady curve. Conclusions: BC subtypes have distinct outcome but also displays different pattern of recurrence over time. This additional information might suggest the convenience of considering different timings and duration of adjuvant treatments depending of BC subtypes. Hazard rates for BC subtypes’ recurrence. Total Lum A Lum B Lum-HER2 HER2 BL TNP-nb Maximum HR 0.006 0.004 0.007 0.008 0.021 0.01 0.008 Time of maximum HR (months) 27.3 39.2 33.2 29.8 18.7 17.9 37.2
STUDIES BASED ON A MALIGNANT TUMOR OF THE RABBIT
Authors: Wade H. Brown, Louise Pearce, Chester M. Van Allen
Journal: The Journal of Experimental Medicine (1924)

A report is given of the results obtained by intratesticular inoculation of a malignant tumor of the rabbit based on a study of the first twenty generations. The subject is presented from the standpoint of variations in growth and malignancy as they occurred with continued transplantation. Essential features of the experimental conditions and of clinical and postmortem observations are condensed and recorded graphically. On analyzing the results of these experiments, it was found that many changes had occurred in the behavior of the tumor during transplantation, but that the changes were of a very irregular character and as a rule did not proceed constantly in any given direction. Moreover, the evidence as to the effect of transplantation on the growth and malignancy of the tumor was contradictory in that there was a great deal of evidence to show that there had been a decided increase in the activity and capacity for growth on the part of the tumor cells. But, with the exception of a few generations, there was an apparent reduction in the incidence and percentage distribution of secondary tumors, while the death rate was unaltered or actually diminished. It was believed that this paradoxical situation afforded a basis for an explanation of the results that had been obtained by transplantation.
Novel in vivo imaging of acute chemotherapy-induced vascular toxicity.
Authors: H. Bar-Joseph, I. Ben-Aharon, R. Shalgi, M. Tzabari, G. Tzarfaty, S. M. Stemmer
Journal: Journal of Clinical Oncology (2010)

e13539 Background: Among the known chemotherapy-related toxicities, direct vascular injury is the least characterized compared to other established side effects. Studies performed using organ cultures have shown that doxorubicin may induce apoptosis of endothelial cells leading to impairment of the vasodilatory response of arteries. Our aim was to establish real-time, in vivo molecular imaging platform in mice in order to evaluate the potential vascular toxicity of doxorubicin. Methods: Gonads(ovaries and testes) served as a prototype for evaluating toxicity in normal tissues. Femoral artery was imaged as a control vessel. The blood flow in the gonad and in the femoral arteries of mice injected with doxorubicin (10 mg/kg intravenously) was measured during and after doxorubicin administration to capture in real time the blood flow. Gonadal blood flow was imaged by ultrasound biomicroscopy (Vevo2100), using microbubbles as a contrast agent and by fluorescence optical imaging system, equipped with confocal fibered microscopy (Cellvizio). Femoral artery blood flow was imaged by Doppler ultrasound. Results: We have established a platform of innovative high resolution molecular imaging, suitable for the gonads and the reference blood vessels, that enables us to detect acute on-line chemotherapy-induced effects in the same individuals and follow them over time. Using microbubbles as the contrast agent allowed us to observe a 30% (p<0.05) decrease in ovarian blood flow already 3 minutes after doxorubicin injection. The same was true for the femoral artery blood flow. Cellvizio imaging indicated that small to medium size blood vessels were damaged at the same time window after doxorubicin injection; Small vessels collapsed while the wall of medium size vessels disintegrated. Conclusions: The acute reduction in ovarian and femoral artery blood flow and the impairment of the blood vessels wall may represent an acute universal doxorubicin related vascular toxicity, an initial event in organ injury. Using high resolution innovative imaging modules enabled us to trace in vivo acute effects of doxorubicin in the same individuals throughout an extended period of time. No significant financial relationships to disclose.
Nemorubicin hydrochloride (nemorubicin) in combination with cisplatin (cDDP): Phase I in patients (pts) with hepatocellular carcinoma (HCC)
Authors: F. Fiore, C. D. Gadaleta, C. Granetto, M. Middleton, R. Sorio, R. Labianca, O. Valota, R. N. Pirotta, R. Battaglia, F. Izzo
Journal: Journal of Clinical Oncology (2008)

2572
Primary Care “Provider” and Professional Identity—Reply
Authors: Allan H. Goroll
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression
Authors: Valerie A Gerriets, Rigel J Kishton, Marc O Johnson, Sivan Cohen, Peter J Siska, Amanda G Nichols, Marc O Warmoes, Aguirre A de Cubas, Nancie J MacIver, Jason W Locasale, Laurence A Turka, Andrew D Wells, Jeffrey C Rathmell
Journal: Nature Immunology (2016)
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
Authors: Hanna W van Steenbergen, Daniel Aletaha, Liesbeth J J Beaart-van de Voorde, Elisabeth Brouwer, Catalin Codreanu, Bernard Combe, João E Fonseca, Merete L Hetland, Frances Humby, Tore K Kvien, Karin Niedermann, Laura Nuño, Sue Oliver, Solbritt Rantapää-Dahlqvist, Karim Raza, Dirkjan van Schaardenburg, Georg Schett, Liesbeth De Smet, Gabriella Szücs, Jirí Vencovský, Piotr Wiland, Maarten de Wit, Robert L Landewé, Annette H M van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2016)

Background During the transition to rheumatoid arthritis (RA) many patients pass through a phase characterised by the presence of symptoms without clinically apparent synovitis. These symptoms are not well-characterised. This taskforce aimed to define the clinical characteristics of patients with arthralgia who are considered at risk for RA by experts based on their clinical experience. Methods The taskforce consisted of 18 rheumatologists, 1 methodologist, 2 patients, 3 health professionals and 1 research fellow. The process had three phases. In phase I, a list of parameters considered characteristic for clinically suspect arthralgia (CSA) was derived; the most important parameters were selected by a three-phased Delphi approach. In phase II, the experts evaluated 50 existing patients on paper, classified them as CSA/no-CSA and indicated their level of confidence. A provisional set of parameters was derived. This was studied for validation in phase III, where all rheumatologists collected patients with and without CSA from their outpatient clinics. Results The comprehensive list consisted of 55 parameters, of which 16 were considered most important. A multivariable model based on the data from phase II identified seven relevant parameters: symptom duration &lt;1 year, symptoms of metacarpophalangeal (MCP) joints, morning stiffness duration ≥60 min, most severe symptoms in early morning, first-degree relative with RA, difficulty with making a fist and positive squeeze test of MCP joints. In phase III, the combination of these parameters was accurate in identifying patients with arthralgia who were considered at risk of developing RA (area under the receiver operating characteristic curve 0.92, 95% CI 0.87 to 0.96). Test characteristics for different cut-off points were determined. Conclusions A set of clinical characteristics for patients with arthralgia who are at risk of progression to RA was established.
Effects of ParentCorps in Prekindergarten on Child Mental Health and Academic Performance
Authors: Laurie Miller Brotman, Spring Dawson-McClure, Dimitra Kamboukos, Keng-Yen Huang, Esther J. Calzada, Keith Goldfeld, Eva Petkova
Journal: JAMA Pediatrics (2016)

Low-income minority children living in urban neighborhoods are at high risk for mental health problems and underachievement. ParentCorps, a family-centered, school-based intervention in prekindergarten, improves parenting and school readiness (ie, self-regulation and preacademic skills) in 2 randomized clinical trials. The longer-term effect on child mental health and academic performance is not known.
BIC and miR-155 Are Highly Expressed in Hodgkin, Primary Mediastinal and Diffuse Large B Cell Lymphomas.
Authors: Joost Kluiver, Sibrand Poppema, Debora de Jong, Tjasso Blokzijl, Geert Harms, Susan Jacobs, Bart-Jan Kroesen, Anke van den Berg
Journal: Blood (2005)
Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience.
Authors: Claudiu Plesa, Quoc-Hung Le, Youcef Chelghoum, Mohamed Elhamri, Isabelle Tigaud, Bruno Anglaret, Sophie Ducastelle, Marie-Claire Perrin, Frank Nicolini, Amine Belhabri, Jacques Troncy, Anne Thiebaut, Daniela Revesz, Eric Wattel, Charles Dumontet, Mauricette Michallet, Xavier Thomas
Journal: Blood (2007)